Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Clover Health Investments Shows Why It Often Pays to Redeem SPAC Shares

By Will Ashworth, InvestorPlace Contributor

Clover Health trades well below its original $10 IPO price. Here’s why the shareholders who redeemed their CLOV stock are ahead of the game.  

10 Shy Blue-Chip Stocks That Deserve the Spotlight

By Will Ashworth, InvestorPlace Contributor

If you’re looking for shy blue-chip stocks to buy, here are 10 with lower-than-average trading volumes to get you on your way. 

It’s Time to Send Out an SOS for the Battered Crypto Miner

By Will Ashworth, InvestorPlace Contributor

Short sellers have made accusations about SOS Limited in recent weeks. It will be hard for investors to trust SOS stock as a result. 

The Odds of Pershing Square Finding a Target Rise by the Day

By Will Ashworth, InvestorPlace Contributor

It’s been eight months since Bill Ackman raised $4 billion. Until he announces a target, PSTH stock won’t be going anywhere but sideways. 

Zomedica’s Early Launch Is Music to Shareholders’ Ears

By Will Ashworth, InvestorPlace Contributor

Zomedica launched its Truforma point-of-care diagnostic platform March 16, ahead of schedule. That’s excellent news if you own ZOM stock.

Load More